A Comparison of Bevacizumab Plus TAS-102 and TAS-102 Monotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis

BackgroundsAs a new oral chemotherapy drug, TAS-102 is currently recommended as the third-line treatment for metastatic colorectal cancer (mCRC). Recently, studies have reported the efficacy of TAS-102 combined with bevacizumab in colon cancer patients after standard treatment fails. Here, we evalua...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Xiaochen Chen, Huafeng Qiu, Yunwang Chen, Mingxing Wang, Pengfei Zhu, Shuangyue Pan, Yaya Deng, Liu Yang, Zheling Chen
Formato: article
Lenguaje:EN
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://doaj.org/article/5a76542d8711429db90335abfcc39a75
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!